Presentation on Tuesday, June 7th, at 10:00 AM PT
Westlake Village, California--(Newsfile Corp. - June 1, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it will be presenting at the 12th annual Invitational on Tuesday, June 7th at 10:00 AM PT at the Four Seasons Westlake Village.
Satellos Co-Founder and CEO, Frank Gleeson will be giving the presentation.
"We are proud to be hosting our 12th annual installment of the Invitational at a new and fantastic venue no less. I want to build on the incredible momentum generated from last October and can not wait to host the patrons and execs who have supported us through thick and thin. For the past 15 years, LD has proven that you can go to an investor conference and actually have a good time while discovering interesting companies." stated Chris Lahiji, Founder of LD Micro.
"The LD Micro Invitational is one of the premier forums for connecting with both US investors and industry leaders. We are delighted to be presenting at the conference and sharing the Satellos story with the influential audience attending this year's event," said Frank Gleeson, President and CEO, Satellos Bioscience Inc. "As we continue to make great strides in the battle against Duchenne and other muscular dystrophies, opportunities like LD Micro allow us to share our cutting-edge science and progress with a growing number of important stakeholders."
Event: LD Micro Invitational
Date: Thursday, June 7th
Time: 10:00 AM PT
Webcast:https://ldinv12.mysequire.com/
Summary of LD Micro Invitational (XII)
The 2022 LD Micro Invitational will be held at the Four Seasons Westlake Village from June 7th to the 9th.
This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.
For more info, please contact Mr. Dean "The Dream" Summers.
Dean@ldmicro.com
About Satellos Bioscience Inc.
Satellos is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has shown how defects in a process known as stem cell "polarity", which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the continuous and accumulating damage their muscles experience. Satellos' lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. For more information about or to discuss potential collaborations with Satellos concerning our discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, PhD, Director - Business Development at rmitchell@satellos.com or visit Satellos.com.
About LD Micro
LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies.
http://www.ldmicro.com
Contact:
Christina Cameron
Investor Relations
Satellos Bioscience Inc.
ccameron@satellos.com
647.660.1780
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125631
